vs
Side-by-side financial comparison of NORTHERN OIL & GAS, INC. (NOG) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $610.2M, roughly 1.3× NORTHERN OIL & GAS, INC.). Insulet Corporation runs the higher net margin — 13.0% vs -11.6%, a 24.6% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -72.6%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $43.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 4.3%).
Marathon Oil Corporation was an American company engaged in hydrocarbon exploration. In November 2024, it was acquired by ConocoPhillips and absorbed into the company.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
NOG vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $610.2M | $783.7M |
| Net Profit | $-70.7M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | -11.6% | 13.0% |
| Revenue YoY | -72.6% | 31.2% |
| Net Profit YoY | -198.7% | 0.9% |
| EPS (diluted) | $-0.73 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $610.2M | — | ||
| Q4 25 | $610.2M | $783.7M | ||
| Q3 25 | $556.6M | $706.3M | ||
| Q2 25 | $706.8M | $649.1M | ||
| Q1 25 | $602.1M | $569.0M | ||
| Q4 24 | $515.0M | $597.5M | ||
| Q3 24 | $753.6M | $543.9M | ||
| Q2 24 | $560.8M | $488.5M |
| Q1 26 | $-70.7M | — | ||
| Q4 25 | $-70.7M | $101.6M | ||
| Q3 25 | $-129.1M | $87.6M | ||
| Q2 25 | $99.6M | $22.5M | ||
| Q1 25 | $139.0M | $35.4M | ||
| Q4 24 | $71.7M | $100.7M | ||
| Q3 24 | $298.4M | $77.5M | ||
| Q2 24 | $138.6M | $188.6M |
| Q1 26 | — | — | ||
| Q4 25 | 80.4% | 72.6% | ||
| Q3 25 | 78.7% | 72.2% | ||
| Q2 25 | 82.8% | 69.7% | ||
| Q1 25 | 81.1% | 71.9% | ||
| Q4 24 | 77.4% | 72.1% | ||
| Q3 24 | 85.8% | 69.3% | ||
| Q2 24 | 82.0% | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | -5.5% | 18.7% | ||
| Q3 25 | -22.6% | 16.7% | ||
| Q2 25 | 24.9% | 18.7% | ||
| Q1 25 | 38.1% | 15.6% | ||
| Q4 24 | 25.8% | 18.3% | ||
| Q3 24 | 57.6% | 16.2% | ||
| Q2 24 | 39.0% | 11.2% |
| Q1 26 | -11.6% | — | ||
| Q4 25 | -11.6% | 13.0% | ||
| Q3 25 | -23.2% | 12.4% | ||
| Q2 25 | 14.1% | 3.5% | ||
| Q1 25 | 23.1% | 6.2% | ||
| Q4 24 | 13.9% | 16.9% | ||
| Q3 24 | 39.6% | 14.2% | ||
| Q2 24 | 24.7% | 38.6% |
| Q1 26 | $-0.73 | — | ||
| Q4 25 | $-0.67 | $1.42 | ||
| Q3 25 | $-1.33 | $1.24 | ||
| Q2 25 | $1.00 | $0.32 | ||
| Q1 25 | $1.39 | $0.50 | ||
| Q4 24 | $0.71 | $1.38 | ||
| Q3 24 | $2.96 | $1.08 | ||
| Q2 24 | $1.36 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.3M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $2.1B | $1.5B |
| Total Assets | $5.4B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $14.3M | — | ||
| Q4 25 | $14.3M | — | ||
| Q3 25 | $31.6M | — | ||
| Q2 25 | $25.9M | — | ||
| Q1 25 | $33.6M | — | ||
| Q4 24 | $8.9M | — | ||
| Q3 24 | $34.4M | — | ||
| Q2 24 | $7.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $930.8M | ||
| Q3 25 | $2.3B | $934.9M | ||
| Q2 25 | $2.4B | $939.0M | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $2.0B | $1.4B | ||
| Q2 24 | $1.9B | $1.4B |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $1.5B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $2.4B | $1.5B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.3B | $1.2B | ||
| Q3 24 | $2.3B | $1.1B | ||
| Q2 24 | $2.1B | $998.4M |
| Q1 26 | $5.4B | — | ||
| Q4 25 | $5.4B | $3.2B | ||
| Q3 25 | $5.5B | $3.0B | ||
| Q2 25 | $5.7B | $3.5B | ||
| Q1 25 | $5.7B | $3.5B | ||
| Q4 24 | $5.6B | $3.1B | ||
| Q3 24 | $5.1B | $3.0B | ||
| Q2 24 | $4.7B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | 1.13× | 0.61× | ||
| Q3 25 | 1.05× | 0.68× | ||
| Q2 25 | 0.98× | 0.64× | ||
| Q1 25 | 0.96× | 1.21× | ||
| Q4 24 | 1.02× | 1.07× | ||
| Q3 24 | 0.84× | 1.21× | ||
| Q2 24 | 0.91× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $312.6M | $183.3M |
| Free Cash FlowOCF − Capex | $43.2M | $48.2M |
| FCF MarginFCF / Revenue | 7.1% | 6.2% |
| Capex IntensityCapex / Revenue | 31.5% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $312.6M | — | ||
| Q4 25 | $312.6M | $183.3M | ||
| Q3 25 | $423.1M | $125.7M | ||
| Q2 25 | $362.1M | $196.5M | ||
| Q1 25 | $407.4M | $63.8M | ||
| Q4 24 | $290.3M | $147.7M | ||
| Q3 24 | $385.8M | $98.5M | ||
| Q2 24 | $340.5M | $96.5M |
| Q1 26 | $43.2M | — | ||
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M |
| Q1 26 | 7.1% | — | ||
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% |
| Q1 26 | 31.5% | — | ||
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | 3.64× | 8.73× | ||
| Q1 25 | 2.93× | 1.80× | ||
| Q4 24 | 4.05× | 1.47× | ||
| Q3 24 | 1.29× | 1.27× | ||
| Q2 24 | 2.46× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NOG
| Oil and Gas Sales | $447.7M | 73% |
| Gain on Commodity Derivatives, Net | $159.3M | 26% |
| Other Revenue | $3.1M | 1% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
